Early Trastuzumab Interruption and Recurrence-Free Survival in <i>ERBB2</i>-Positive Breast Cancer
Robert S. Copeland-Halperin, Mohammed Al‐Sadawi, Sujata Patil, Jennifer E. Liu, Richard M. Steingart, Chau T. Dang, Anthony F. Yu
Abstract
This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.
Topics & Concepts
MedicineTrastuzumabBreast cancerOncologyInternal medicineCancerHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research